Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 6 Possible therapeutic targets to decrease hepatic steatosis

Published byМирјана Ђукић Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 6 Possible therapeutic targets to decrease hepatic steatosis"— Presentation transcript:

1 Figure 6 Possible therapeutic targets to decrease hepatic steatosis
Figure 6 | Possible therapeutic targets to decrease hepatic steatosis. Interventions designed to decrease triglyceride (TG) synthesis, increase lipolysis, increase fatty acid (FA) oxidation, or increase very-low-density lipoprotein (VLDL) secretion could decrease hepatic TG content. ER, endoplasmic reticulum. Gluchowski, N. L. et al. (2017) Lipid droplets and liver disease: from basic biology to clinical implications Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Download ppt "Figure 6 Possible therapeutic targets to decrease hepatic steatosis"

Similar presentations

Diet Study for Nonalcoholic Fatty Liver Disease 022509 Lab meeting.

Diet Study for Nonalcoholic Fatty Liver Disease Lab meeting.
Figure 1 Proposed risk stratification for patients with NAFLD

Figure 1 Proposed risk stratification for patients with NAFLD
Figure 6 Cholesterol metabolism in obesity-related glomerulopathy

Figure 6 Cholesterol metabolism in obesity-related glomerulopathy
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Volume 148, Issue 4, Pages (April 2015)

Volume 148, Issue 4, Pages (April 2015)
Figure 5 Dendritic cells in liver inflammation

Figure 5 Dendritic cells in liver inflammation
Figure 1 Contribution of the gut microbiota

Figure 1 Contribution of the gut microbiota
Figure 4 Activation of clopidogrel via cytochrome P450

Figure 4 Activation of clopidogrel via cytochrome P450
Figure 5 Therapeutic paradigms for interfering with the brain–gut axis

Figure 5 Therapeutic paradigms for interfering with the brain–gut axis
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Pathophysiological aspects of insulin

Figure 1 Pathophysiological aspects of insulin
Figure 5 Lipid droplet consumption

Figure 5 Lipid droplet consumption
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Worldwide incidence of CCA

Figure 1 Worldwide incidence of CCA
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Biosimilar development process

Figure 1 Biosimilar development process
Figure 2 Effect of PPIs on gastric physiology

Figure 2 Effect of PPIs on gastric physiology

Similar presentations

Ads by Google